| 000 | 01658 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514033803.0 | ||
| 264 | 0 | _c20020712 | |
| 008 | 200207s 0 0 eng d | ||
| 022 | _a1465-3249 | ||
| 024 | 7 |
_a10.1080/146532400539107 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBraunschweig, I | |
| 245 | 0 | 0 |
_aHigh CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. _h[electronic resource] |
| 260 |
_bCytotherapy _c2000 |
||
| 300 |
_a105-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntigens, CD34 _xmetabolism |
| 650 | 0 | 4 | _aBlood Component Removal |
| 650 | 0 | 4 |
_aBlood Transfusion, Autologous _xadverse effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Mobilization |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMirza, N Q | |
| 700 | 1 | _aRondon, G | |
| 700 | 1 | _aLauppe, J | |
| 700 | 1 | _aMehra, R | |
| 700 | 1 | _aGajewski, J | |
| 700 | 1 | _aKörbling, M | |
| 700 | 1 | _aHuh, Y O | |
| 700 | 1 | _aGeisler, D | |
| 700 | 1 | _aGee, A P | |
| 700 | 1 | _aChamplin, R | |
| 700 | 1 | _aPrzepiorka, D | |
| 773 | 0 |
_tCytotherapy _gvol. 2 _gno. 2 _gp. 105-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/146532400539107 _zAvailable from publisher's website |
| 999 |
_c11938791 _d11938791 |
||